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Abstract 
Hypertension is an alarming public health problem among Chinese. The present study 
evaluated the prescribing patterns, discontinuation and switching profiles of antihypertensive 
agents and their associated factors in one Hong Kong Chinese population.  Data were 
retrieved from computerized records for patients prescribed anti-hypertensive agents in 
government primary care clinics of Hong Kong from January, 2004 to June, 2007.  A total of 
1,069,836 antihypertensive drug visits, representing 67,028 patients, were analyzed. The most 
commonly prescribed drugs were Calcium Channel Blockers (CCBs) (49%), β-Blockers (BBs) 
(46%) and Angiotensin-Converting Enzyme Inhibitors (ACEIs) (19%). Thiazide diuretic 
prescribing was low (13%) and on the decline (14% in 2004 to 12% in 2007). Prescribing of 
ACEIs was rising (16% in 2004 to 23% in 2007). Patients’ age, gender, and socio-economic 
status were independent predictors of class of anti-hypertensive prescribed but explained less 
than 3.5% of the variation observed.  Drug discontinuation was highest for BBs (21%) and 
lowest for CCBs (12%). The high rates of discontinuation in BBs remained apparent after 
controlling for confounding variables. Switching was less common than discontinuation and 
was most likely with thiazide diuretics.  To summarize, prescribing of CCBs and BBs were 
high and that of thiazide diuretics particularly low in this Chinese population when compared 
with international trends.  CCBs may be a particularly favorable antihypertensive treatment 
in Chinese, given the high discontinuation rates of BBs and international guidelines advising 
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against the use of BBs as first-line therapy. The low use of thiazide diuretics warrants further 
clinical and cost effectiveness studies among Chinese.  
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Introduction 
Hypertension is a global health challenge due to its high and rapidly growing prevalence in 
Western countries1,2 and also in the Asia pacific region including China.3-5  It remains 
generally poorly controlled6, 7 and has been reported as the most common global risk factor 
for cardiovascular morbidity and mortality, thus carrying a huge public health burden.1, 3   
 
Regarding the drug treatment of hypertension, the World Health Organization (1999),8 the 
National Heart Foundation of Australia (1999)9 and the European Society of Hypertension 
(2003)10 recommended any major classes of antihypertensive agents as the first-line drugs 
subject to physicians’ discretion, while the British Hypertension Society (1999)11 and the 
Seventh report of the Joint National Committee (JNC-VII, 2003)12 supported the use of 
thiazide diuretics as the best first-line prescription in view of accumulating trial evidence 
showing its efficacy, in addition to its affordability. However, these international guidelines 
are based largely on studies conducted among Caucasian subjects in western countries. It is 
unknown whether the existing literatures based on Caucasian subjects can be generalized to 
Chinese patients and even small ethnic differences may bear large implications for health 
resources.13   
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There is also a paucity of health services research in the international literature on the 
treatment of hypertension in China, despite the high prevalence of hypertension in China and 
the fact that China has a population of 1.29 billion (around 20% of the world population).14 
The prescribing patterns of anti-hypertensive agents for Chinese hypertensive patients have 
not been documented in large studies, and thus the implications for effectiveness and 
cost-effectiveness are not known. Given that persistence with antihypertensive drugs is known 
to reduce morbidity and mortality,15, 16 understanding of discontinuation and switching 
profiles are also important in the choice of antihypertensive drug prescription.   
 
Although studies comparing drug discontinuation rates are often based on randomized 
controlled trials17-20 such studies can be limited due to selection bias21, 22 and therefore health 
services-based studies are also a valuable source of evidence.23-25 In the present study we 
report a recent analysis of the trends of physician prescriptions of the major antihypertensive 
classes among Chinese patients in primary care clinics in the public healthcare sector in Hong 
Kong, China.  We also compare the likelihood of discontinuation and switching among 
various antihypertensive drug classes, and report the epidemiological and clinical factors 
associated with anti-hypertensive prescription for each drug class. 
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Materials and Methods 
Data  
The Hospital Authority (HA) of Hong Kong, which provides free or low cost primary and 
secondary care as part of the public health care sector, adopted a comprehensive computerized 
patient recording system in 2000 which includes patients’ clinical and demographic 
parameters, as well as investigation results and drug prescription details.  The resultant 
database set up by the HA has research as one of its objectives,26 and has been evaluated in a 
previous study reporting high completeness in terms of patients’ demographic information 
(100%) and prescription details (99.98%).27  During each clinic visit, patient demographics 
are entered by clinic staffs according to patients’ identity documents, and drug prescriptions 
must be entered by the attending physicians into the computer system and are double checked 
by the dispensing HA pharmacists. These computerized records are the sole portal of 
information entry by physicians at each patient visit in all primary care clinics run by the HA.   
 
Study Cohort 
The study subjects were adult patients (aged > 18 year-old) visiting HA primary care clinics at 
least once during the study period January, 2004 to June, 2007 inclusive. Because of the 
disruption cased by the Severe Acute Respiratory Syndrome (SARS) outbreak (April to 
October, 2003) we have not attempted to use data accumulated between 2000 and 2003. The 
 6
inclusion criteria included General Out-Patient Clinics (GOPCs), Family Medicine Specialist 
Clinics (FMSCs) or Staff Clinics (SCs) in the New Territory East (NTE) cluster of Hong 
Kong, which provides primary healthcare services to around 1.3 million residents, 
representing 17.2% of the Hong Kong population.28 This cluster is further divided into 3 
separate geographical regions, namely Shatin, Tai-Po and the North district, from the most 
urbanized to the most rural regions respectively. 
 
Visits at which at least one antihypertensive drug was prescribed were retrieved (thereafter 
termed “antihypertensive drug visits”). We excluded patients with known concomitant 
cardiovascular risk factors (diabetes, lipid disorders, coronary heart disease, stroke) or 
suffering from conditions which potentially confound antihypertensive prescription choice 
(benign prostatic hypertrophy, gout, chronic obstructive pulmonary diseases, asthma, heart 
failure). A complete list of these conditions has been published elsewhere.27  
 
To maintain confidentiality, no personal identifiers had been disclosed.  The study was 
approved by the NTE cluster, Hospital Authority and the Survey and Behavioural Research 
Ethics Committee (SBREC), the Chinese University of Hong Kong. 
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Outcomes and Associated Factors 
The main outcome measure was the drug class prescribed in each antihypertensive drug visit 
as a proportion of patient visits where antihypertensive agents were issued, annually from 
January, 2004 to June, 2007. These include α-blockers, β-blockers (BBs), thiazide diuretics, 
Calcium Channel Blockers (CCBs), Angiotensin Converting Enzyme Inhibitors (ACEIs), 
Angiotensin Receptor Blockers (ARBs), combination therapy (defined as prescription with 
single pills consisting of at least 2 active antihypertensive ingredients), polytherapy (defined 
as prescription of more than one antihypertensive agent in a single visit) and miscellaneous 
(Potassium-sparing diuretics, vasodilators and loop diuretics).  In the study period Amiloride 
hydrochloride combined with hydrochlorothiazide represents 99.96% of the formulation of 
combination therapy received by our patients. 
 
Factors which may influence choice of antihypertensive agent prescription (and for which 
data was available) included patients’ age, gender, payment status (Fee waivers vs. payers, 
US$5.77 per visit inclusive of drug and investigation expenses), Service types (GOPCs, 
FMSCs or SCs), district of residence, visit type (new or subsequent visits) and the calendar 
years of prescription.  In our sample, fee waivers are almost exclusively residents receiving 
social security allowances from the government.  To qualify for fee waiving patients must be 
comprehensively assessed by a medical social worker who determines their inability to pay 
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for medical consultation fee.  Accordingly payment status is regarded as a proxy measure for 
socioeconomic status. 
 
The secondary outcome measure was the 180 day cumulative incidence of discontinuation 
and switching and the likelihood of discontinuation and switching, in terms of odds ratios, for 
each drug class using CCBs as a reference.  Discontinuation is defined as the absence of a 
refill prescription on all subsequent antihypertensive drug visits without the issuance of 
another class of antihypertensive drugs, while switching represents absence of a refill 
prescription in subsequent antihypertensive drug visits but replaced with another class of 
antihypertensive drugs, both within the time frame of 180 days.  These definitions of 
discontinuation and switching were similar to previous studies24, 25 except that a longer time 
frame of 180 days was used instead of 90 days, taking into account the common practice of 
prescribing antihypertensive drugs for a period of slightly longer than 90 days in Hong Kong 
primary practice. In comparing discontinuation incidences among different antihypertensive 
drug classes, we included only newly attending patients in our study period since previous use 
of antihypertensive drugs could potentially affect drug tolerability and hence discontinuation 
rate.  They had no records of any antihypertensive prescription in the clinical database and 
therefore were drug naïve patients as far as we can tell. 
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Statistical Analysis 
The Statistical Package for Social Sciences (SPSS) version 13.0 was used for all statistical 
analyses. We used antihypertensive drug visit as one unit of analysis for studying prescription 
patterns, and individual patient as one unit of analysis for cumulative incidences of drug 
discontinuation and switching.  We evaluated the annual trend of antihypertensive drug 
prescription for each drug class, in terms of proportions of all antihypertensive drug visits, 
from 2004 to 2007.  We also compared the patterns of prescribing monotherapy, polytherapy 
and combination therapy.  Categorical variables were analyzed by χ2 tests.  To study the 
association between antihypertensive drug prescription and patient characteristics, five 
separate binary logistic multivariate regression analyses were performed to control for all of 
the above associated factors.  The five distinct outcomes were prescription of each of the 
major drug classes for all antihypertensive drug visits, respectively.   
 
We compared the crude incidences of drug discontinuation and switching at 180 days by χ2 
tests among various drug classes, followed by multivariable logistic regression to control for 
all the associated factors.  The odds ratios of discontinuation and switching, respectively, for 
each drug class were studied using CCBs as the reference group.  The forward stepwise 
model was used as a variable selection procedure, and all p values<0.05 were regarded as 
statistically significant. 
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Results 
Subject Characteristics 
We identified 67,113 patients who fulfilled our study inclusion criteria, representing 
1,069,836 antihypertensive drug visits during the study period.  Average age was 65 years 
and the majority were female (59 %).  Among these subjects, 52,237 patients (78%) were 
new attendees within the study period.  The detailed characteristics of this patient population 
have been reported previously.27
 
Annual trends of antihypertensive drug prescription  
Among all antihypertensive drug visits, CCBs (49.4%) and BBs (46.2%) were the most 
commonly prescribed drugs, followed by ACEIs (18.9%), α-blockers (16.3%) thiazide 
diuretics (13.2%), and combination therapy (8.3%) (Figure 1).  Among prescriptions of BBs, 
metoprolol (48.8%) and atenolol (46.7%) constituted the majority while for CCBs, the 
commonest drug was nifedipine (92.4%) followed by diltiazem (5.5%).  The trends of 
prescribing were relatively stable for most classes of antihypertensive agents from 2004 to 
2007. However, prescriptions for thiazide diuretics showed a declining trend from 14.3% in 
2004 to 11.8% in year 2007 (p<0.001), whereas prescription of ACEIs increased significantly 
from 15.9% in year 2004 to 22.7% in year 2007 (p<0.001).  The use of ARBs was 
exceptionally low at 0.17% and remained stable over time. 
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Annual trends of monotherapy, polytherapy & combination therapy  
The majority of patients were on monotherapy (51.4%), followed by two class polytherapy 
(37.0%).  The proportion of subjects prescribed at least 3 classes of antihypertensive drugs 
was therefore low (11.7%) (Table 1).  The most common prescription for two-drug therapy 
consists of BB-CCB polytherapy (13.2%), followed by ACEI-CCB (3.5%).  From 2004 to 
2007, there was a consistent increase in the prescription of ACEI-CCB (3.0% to 4.1%, 
p<0.001) and ACEI-BB polytherapy (2.2% to 3.3%, p<0.001). 
 
Factors associated with class of antihypertensive drug prescribed  
In multivariate logistic regression analysis, age was independently associated with the type of 
anti-hypertensive prescribed (Table 2). Compared with younger patients (<50 year old) 
elderly patients (> 70 years) were less likely to receive BBs (aOR 0.47). Male patients were 
less likely to be prescribed BBs (aOR 0.94) and thiazide diuretics (aOR 0.68). Payment status 
had little effect on the prescription choice. Patients attending FMSC and staff clinics were 
more likely to receive ACEIs (aOR 1.46 to 2.57). The district of residence also had significant 
effects on the prescription choices.  
Regarding the fitness of the models, Nagelkerke r2 ranged from 0.015 to 0.034 for these 
separate regression analyses, reflecting that these associated factors combined explained only 
1.5% to 3.4% of the prescription outcome.  
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Factors associated with antihypertensive drug discontinuation and switching   
The crude cumulative incidence of drug discontinuation at 180 days was the highest for BBs 
(20.8%, 95% C.I. 20.2%, 21.4%), followed by ACEIs (19.8%, 95% C.I. 18.7%, 20.9%), 
α-blockers (18.8%, 95% C.I. 17.6%, 20.0%) and thiazide diuretics (13.7%, 95% C.I. 12.8%, 
14.6%). CCBs had the lowest discontinuation incidence of 12.0% (95% C.I. 11.5%, 12.5%; 
p<0.001). Thiazide diuretics had the highest cumulative incidence of switching at 180 days 
(12.2%, 95% C.I. 11.3%, 13.1%), followed by ACEIs (8.29%, 95% C.I. 7.50%, 9.08%) 
(p<0.001). The cumulative incidences of switching for α-blockers (5.66%, 95% C.I. 4.96%, 
6.36%), BBs (5.72%, 95% C.I. 5.38%, 6.06%) and CCBs (6.24%, 95% C.I. 5.88%, 6.60%) 
were similar.  
When controlled for other associated factors using CCBs as a reference (Table 3), older 
patients were less likely to have drugs discontinued within 180 days after the first-ever 
antihypertensive prescription (aOR 0.51 to 0.65, all p<0.001) but only the eldest group (aged 
> 70 years) showed a significantly lower drug switching rate (aOR 0.79, p<0.001).  Male 
patients were more likely to have drugs discontinued (aOR 1.07, p=0.012) but less likely to 
have drugs switched (aOR 0.77, p<0.001). When compared with CCBs, α-blockers (aOR 3.38) 
and BBs (aOR 2.38) were more likely to be discontinued (aOR 0.725) (both p<0.001).  
Thiazide diuretics were more likely to be switched (aOR 2.16, p<0.001) while BBs were less 
likely to be switched (aOR 0.70, p<0.001) compared with CCBs. 
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Discussion 
Major findings 
In this large study of over a million anti-hypertensive prescriptions issued to patients 
attending primary care clinics within the public healthcare system of Hong Kong from 
January, 2004 to June, 2007 we have found high rates of prescribing of BBs and CCBs, and 
low (and declining) prescribing levels of thiazide diuretics. Independent predictors of class of 
anti-hypertensive prescribed (including age, gender, and socioeconomic status) explained less 
than 3.5% of the variation observed. Drug discontinuation was high for BBs (21%) even after 
controlling for confounding variables. Drug switching was less common than discontinuation 
and was most likely with thiazide diuretics. 
 
Interpretation of findings and relationship with published literature: prescribing 
patterns and trends 
Similar patterns of prescribing to those found in the present study have been reported in 
previous smaller studies in similar settings in the public healthcare system in Hong Kong.29-31 
Practices within the private primary care system in Hong Kong are not well documented, but 
a recent survey of 225 private doctors’ self-reported prescribing behaviour showed CCBs to 
be the most commonly prescribed (31%) followed by ACEIs (28.5%), diuretics (27.5%) and 
BBs (21.2%) with perceived drug efficacy being the top reason given for choice of drug. 
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However, the small size of this study (less than 5% of the private doctor population in Hong 
Kong) and the fact that it recorded self-reported prescribing and not actual prescribing raise 
questions about accuracy and representativeness.32
 
In international studies, patterns and trends in antihypertensive prescribing vary widely 
between countries.33 However in many countries first-line treatment with a thiazide diuretic is 
common practice. In a nation-wide study by Ma et al34 in the USA thiazide diuretics were the 
most commonly prescribed antihypertensive (approximately 50% of patients) with a rising 
trend, followed by BBs and CCBs (approximately 33% each).23 The prescribing of ACEIs was 
found to be decreasing (35% in 2004). Similarly, in a large, nationally-representative study in 
the USA by Stafford et al 2006, high usage of CCBs and thiazide diuretics was reported.35 A 
large study in patients aged over 65 years in Canada reported that diuretics were the most 
commonly prescribed agent in non-diabetics, followed by BBs and ACEIs with all three 
showing a rising trend between 1994 and 2002.36 As shown in Table 4, the prescription 
patterns of various antihypertensive drug classes varied across regions.37-41
Low usage of diuretics has been reported in hypertensive patients of Chinese ethnicity living 
in the USA, when compared with other ethnic groups.40 Suggested factors to explain 
inter-country variation included reimbursement policies, traditions, opinion leaders with 
conflicts of interests, domestic pharmaceutical production, and clinical practice guidelines.33
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Interpretation of findings and relationship with published literature: factors associated 
with different prescribing patterns 
Elder patients in the present study were less likely to receive BBs.  This is in line with 
guidelines highlighting greater efficacy of thiazide diuretics and CCBs in the elderly with 
respect to their lower renin status.42  Similar observations of lower usage of BBs in the 
elderly have also been reported in both local and international studies.37, 38, 43  Male patients 
were less likely to receive thiazide diuretics and BBs than female patients.  Currently there 
are no international authorities which recommend specific antihypertensive drugs according 
to gender. This finding is however consistent with some local studies,31, 43 which suggested 
sexual dysfunction could be a major considering factor when prescribed to male patients30.  
Furthermore, physicians may perceive that thiazide diuretics could cause gouty attacks in 
male populations more frequently.42   
 
The prescription of ARBs was almost twice more likely to be prescribed between 2005 and 
2007 than 2004. This may be due to recent new drug marketing.34, 44 The higher likelihood of 
prescribing ACEIs and ARBs in Family Medicine Specialist Clinics and staff clinics in the 
present study may be due to the availability of newer formularies in these clinics, referral of 
patients from secondary care settings (where prescription patterns may differ), and perhaps 
different patient expectations in these clinics.  The findings that the district of residence, visit 
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types and calendar years were independent associated factors of antihypertensive prescription 
are of interest although the reasons for this cannot be determined from the present study 
design. However, the low weighting of all the significant predictive factors on prescription 
choice indicate that they are of little overall importance to the type of prescription issued. 
Other explanatory factors not measured in this study include physician’s knowledge, views 
and experiences, peer influence, and the considerable marketing influence of the 
pharmaceutical industry within the public healthcare system.45 A small local study reported 
perceived drug effectiveness and tolerability as the most crucial factors in determining 
first-line antihypertensive choice among trainee doctors in Hong Kong, and that more 
experienced trainees revealed higher awareness and adherence to evidence-based guidelines.43  
 
Interpretation of findings and relationship with published literature: discontinuation 
and switching rates 
The six-month discontinuation rate of antihypertensive drugs overall in our present study was 
found to be approximately 25% in each class with the exception of CCBs which was lower 
(18%).  Study results from Burke et al. in 2006 using the United Kingdom General Practice 
Research Database (GPRD) reported a similar overall 6 month discontinuation rates of 20.3% 
(95% C.I. 20.0%, 20.5%)24 among newly diagnosed hypertensive patients using similar 
methodology to the present study.  They found that ARBs, followed by ACEIs, had the 
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lowest class-specific risks of discontinuation.  This is different from our study result where 
we found CCBs to have the lowest discontinuation rate. Our study findings are also different 
from Hughes & McGuire’s evaluation of the discontinuation percentages in 1998, from the 
MEDIPLUS database in UK.46  They found the crude discontinuation rate within 6 months 
of drug initiation to be highest in diuretics (36%), followed by CCBs (31%), ACEIs (31%) 
and BBs (28%).  The percentages of switching therapy in their study was highest in BBs 
(21%) and similar between diuretics (16%), ACEIs (16%) and CCBs (15%),46 but in our 
present study the switching rate for thiazide diuretics was the highest and that for BBs the 
lowest.  Similar studies in Italy by Mazzaglia et al. in 2005 reported ARBs had the lowest 
discontinuation rates, but that of ACEIs and CCBs were similar.25 Thus the discontinuation 
and switching profiles of the present study are somewhat different from Caucasian studies, 
most notably with the low discontinuation rate of CCBs, which raises the possibility of ethnic 
differences. 
 
Strengths and weaknesses of current study 
As far as we are aware, our study is the largest evaluation ever conducted in the Asia Pacific 
region on the prescribing patterns and discontinuation profiles of antihypertensive drugs in 
Chinese patients treated in primary care.  The major strength of our study is therefore the 
robust sample size generated over a 3.5 year period. The strengths and weaknesses of the 
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electronic data base from which this study was drawn has been discussed previously.27 Data 
completeness is high for demographic and prescribing details but lower for coding of specific 
diseases.27 In the present study we excluded patients with coded conditions that might 
influence the choice of anti-hypertensive agent prescribed (exclusion codes). We included 
patients coded with ICPC K86 – uncomplicated hypertension (45.7%) and those without any 
ICPC codes (un-coded group; 54.3%) on the assumption that most of the un-coded patients 
had uncomplicated hypertension. This assumption is based on our previous analysis showing 
that the patient characteristics with the un-coded group are very similar to the K86 group but 
different from exclusion group. Further sub-group analysis supports this assumption in the 
present study; prescribing patterns, trends, and discontinuation rates are very similar in the 
K86 group alone when compared with the results presented in this paper for the larger 
combined sample (results not shown). 
 
Our sample is from only one territory of Hong Kong (NTEC) out of seven such clusters in the 
whole population and therefore is not representative of Chinese patients in other localities. 
However, similar patterns of prescribing to those found in the present study have been 
reported in previous smaller studies in other clusters of Hong Kong29-31 and thus it is likely 
that our findings are generalisable in terms of primary care within the public healthcare 
system in Hong Kong. We cannot of course extrapolate our findings however to the private 
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healthcare sector. However, uncomplicated hypertension is the second commonest condition 
seen in primary care clinics in the public healthcare sector in Hong Kong,47 and available data 
suggests that the vast majority of the population attends the public health services rather than 
the private sector for management of hypertension.48 Thus our findings may well be of 
significance at population level in terms of hypertension management and healthcare costs. 
 
We were unable to study the reasons of discontinuation using the existing database, although 
the discontinuation patterns may be a proxy measure for antihypertensive intolerability, and 
further work is required on this. 
 
Implications for policy and practice 
The present study suggests that CCBs are a particularly acceptable option for use in Chinese 
patients in the age group studied, given their high levels of prescribing and relatively low 
discontinuation profiles. BBs on the other hand were much more likely to be discontinued. 
Given recent evidence on the poorer efficacy of BBs compared with other classes, first line 
use of BBs should be discouraged in line with the recommendations by international 
authorities.42 The rising use of ACEIs should be further explored as both its discontinuation 
and switching profiles were inferior to CCBs among Chinese and costs are higher than other 
prescription alternatives.42 
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The reasons driving the prescription patterns reported in the present study need further 
exploration. Recent major international guidelines - the British National Institute for Clinical 
Excellence (NICE),42 the Canadian Hypertension Education Program,49 and the World Health 
Organization/International Society of Hypertension (WHO/ISH)50 unanimously recommend 
thiazide diuretics as the preferred drug option, whether as first-line or in polytherapy. There is 
no evidence in the present study that any of these international guidelines, nor the large 
international trials that informed them, have had any impact on the prescription patterns 
reported in the present study between 2004 and 2007. In the absence of any such effect from 
international guidelines, it is possible that locally produced Hong Kong guidelines may have 
more of an impact. Influencing prescribing behaviour within the primary care clinics of the 
Hospital Authority (the public healthcare sector) should, in theory, be easier than in the 
private primary care system which is currently unregulated, has no wide-spread quality 
assurance systems in place, and operates on a fee-for-service basis with doctors’ income being 
directly to profit margins relating to consultation fees and drug charges. 
 
The use of thiazide as a first-line agent has substantial support from many studies, but our 
findings of its higher switching rates compared with other classes of antihypertensive drugs 
may reflect the greater incidences of metabolic side effects such as hyponatraemia29. Whether 
such effects are more prominent in patients of Chinese race is not known. Policies to increase 
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the first-line use of thiazides in Hong Kong would potentially lead to considerable savings in 
drug costs, although fuller economic modeling is required before conclusions on 
cost-effectiveness can be reached.42 
 
To conclude, when compared with international trends, the prescription of CCBs and BBs are 
high and that of thiazide diuretics particularly low in this Chinese population attending 
primary care in the public healthcare sector of Hong Kong. CCBs may be a particularly 
favorable antihypertensive treatment in this population given the high discontinuation rates of 
BBs, and recent international guidelines advising against the use of BB in first-line therapy. 
The low use of thiazide diuretics warrants further investigation including both clinical and 
cost effectiveness in this population. Community-wide data on prescription patterns represents 
a crucial information source for health authorities to plan and implement necessary guidelines 
and protocols in the use of antihypertensive agents. 
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Table 1  Patterns of antihypertensive monotherapy, polytherapy and combination 
therapy in primary care clinics in Hong Kong 
 
 2004 
(N=238,034) 
2005 
(N=323,849) 
2006 
(N=333,824) 
2007* 
(N=174,129) 
2004-2007 
(N=1,069,836) 
P 
value
1 class 
 
2 class 
 
>3 classes 
130,106 (54.66%) 
(54.46%, 54.86%) 
86,495 (36.34%) 
(36.14%, 36.53%) 
21,433 (9.00%) 
(8.89%, 9.12%) 
155,402 (47.99%) 
(47.81%, 48.16%) 
123,231 (38.1%) 
(37.88%, 38.22%) 
45,216 (13.96%) 
(13.84%, 14.08%) 
174,527 (52.28%) 
(52.11%, 52.45%) 
121,808 (36.49%) 
(36.33%, 36.65%) 
37,489 (11.23%) 
(11.12%, 11.34%) 
89,465 (51.38%) 
(51.14%,51.61%) 
63,920 (36.71%) 
(36.48%,36.94%) 
20,744 (11.91%) 
(11.76%,12.07%) 
549,500 (51.36%) 
(51.27%, 51.46%) 
395,454 (36.96%) 
(36.87%, 37.06%) 
124,882 (11.67%) 
(11.61%, 11.73%) 
<0.001 
Diuretics- 
BB 
7,316 (3.07%) 
(3.00%, 3.14%) 
10,277 (3.17%) 
(3.11%, 3.23%) 
9,590 (2.87%) 
(2.82%, 2.93%) 
4,425 (2.54%) 
(2.47%, 2.62%) 
31,608 (2.95%) 
(2.92%, 2.99%) 
<0.001 
Diuretics- 
ACEI 
1,936 (0.81%) 
(0.78%,0.85%) 
2,775 (0.86%) 
(0.83%, 0.89%) 
3,083 (0.92%) 
(0.89%, 0.96%) 
1,878 (1.08%) 
(1.03%, 1.13%) 
9,672 (0.90%) 
(0.89%, 0.92%) 
<0.001 
Diuretics- 
CCB 
3,395 (1.43%) 
(1.38%, 1.47%) 
4,338 (1.34%) 
(1.30%, 1.38%) 
4,198 (1.26%) 
(1.22%, 1.30%) 
2,067 (1.19%) 
(1.14%, 1.24%) 
13,998 (1.31%) 
(1.29%, 1.33%) 
<0.001 
BB- 
CCB 
31,333 (13.16%) 
(13.03%, 13.30%) 
43,310 (13.37%) 
(13.26%, 13.49%) 
43,869 (13.14%) 
(13.03%,13.26%) 
22,747 (13.06%) 
(12.91%,13.22%) 
141,259 (13.20%) 
(13.14%, 13.27%) 
0.006 
ACEI- 
CCB 
7,014 (2.95%) 
(2.88%, 3.02%) 
10,585 (3.27%) 
(3.21%, 3.33%) 
12,119 (3.63%) 
(3.57%, 3.69%) 
7,204 (4.14%) 
(4.04%, 4.23%) 
36,922 (3.45%) 
(3.42%, 3.49%) 
<0.001 
ACEI- 
BB 
5,298 (2.23%) 
(2.17%, 2.29%) 
8,161 (2.52%) 
(2.47%, 2.57%) 
9,803 (2.94%) 
(2.88%, 2.99%) 
5,824 (3.34%) 
(3.26%, 3.43%) 
29,086 (2.72%) 
(2.69%, 2.75%) 
<0.001 
Other 
combinations* 
7,388 (3.10%) 
(3.03%, 3.17%) 
10,102 (3.12%) 
(3.06%, 3.18%) 
10,341 (3.10%) 
(3.04%, 3.16%) 
5,484 (3.15%) 
(3.07%, 3.23%) 
33,315 (3.11%) 
(3.08%, 3.15%) 
0.770 
 
(CCBs: Calcium Channel Blockers; ACEIs: Angiotensin Converting Enzyme Inhibitors.  N is the total numbers of prescription episodes for the 
corresponding year(s).  Percentages by row were in parentheses, and the p values represent chi square tests of homogeneity testing prescription 
proportions of the respective antihypertensive drug classes among four calendar years  The figures are number (% within each year) and 
corresponding 95% confidence intervals *Other combinations refer to prescription of > 2 active antihypertensive ingredients in one-pill) 
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Table 2 Factors associated with antihypertensive drug class prescription in 
primary care clinics in Hong Kong 
 
 α-blockers β-blockers Thiazide CCB ACEI 
  
aOR (95% CI) 
 
aOR (95% CI) 
 
aOR (95% CI) 
 
aOR (95% CI) 
 
aOR (95% CI) 
Patient age 
<50 
50-59 
60-69 
>70 
 
1.00 (reference) 
1.56 (1.52, 1.60) 
2.66 (2.59, 2.72) 
3.71 (3.63, 3.80) 
 
1.00 (reference) 
0.83 (0.82, 0.84) 
0.65 (0.64, 0.66) 
0.47 (0.46, 0.48) 
 
1.00 (reference) 
1.13 (1.11, 1.15) 
1.18 (1.15, 1.20) 
1.12 (1.10, 1.14) 
 
1.00 (reference) 
1.25 (1.23, 1.27) 
1.53 (1.51, 1.55) 
2.00 (1.98, 2.03) 
 
1.00 (reference) 
1.03 (1.01, 1.05)* 
1.04 (1.03, 1.06) 
1.07 (1.05, 1.09) 
Sex 
Female 
Male 
 
1.00 (reference) 
1.41 (1.39, 1.42) 
 
1.00 (reference) 
0.94 (0.93, 0.95) 
 
1.00 (reference) 
0.68 (0.67, 0.69) 
 
1.00 (reference) 
1.36 (1.35, 1.37) 
 
1.00 (reference) 
1.45 (1.43, 1.46) 
Payment 
status 
Fee waivers 
Payers 
 
 
1.00 (reference) 
0.96 (0.95, 0.97) 
 
 
1.00 (reference) 
1.08 (1.07, 1.09) 
 
 
1.00 (reference) 
NS 
 
 
1.00 (reference) 
1.09 (1.08, 1.10) 
 
 
1.00 (reference) 
1.05 (1.04, 1.07) 
Service Type 
GOPC 
FMSC 
Staff clinic 
 
1.00 (reference) 
0.40 (0.38, 0.41) 
0.55 (0.46, 0.65) 
 
1.00 (reference) 
0.90 (0.89, 0.92) 
0.92 (0.85, 0.99)** 
 
1.00 (reference) 
0.78 (0.75, 0.80) 
0.88 (0.79, 0.99)** 
 
1.00 (reference) 
0.80 (0.78, 0.81) 
0.39 (0.36, 0.43) 
 
1.00 (reference) 
2.57 (2.52, 2.62) 
1.46 (1.33, 1.61) 
Residence  
district 
Shatin 
Taipo 
Northern 
Others 
 
 
1.00 (reference) 
1.75 (1.73, 1.77) 
1.39 (1.37, 1.41) 
1.15 (1.12, 1.18) 
 
 
1.00 (reference) 
0.81 (0.80,0.81) 
1.02 (1.01, 1.03)* 
0.97 (0.95, 0.98) 
 
 
1.00 (reference) 
0.69 (0.68, 0.70) 
0.74 (0.73, 0.76) 
0.90 (0.88, 0.92) 
 
 
1.00 (reference) 
0.96 (0.95, 0.97) 
0.91 (0.90, 0.92) 
0.99 (0.98, 1.01)^ 
 
 
1.00 (reference) 
1.06 (1.04, 1.07) 
1.23 (1.22, 1.25) 
1.26 (1.23, 1.28) 
Visit Type 
First visit 
Subsequent 
visit 
 
1.00 (reference) 
1.17 (1.15, 1.18) 
 
1.00 (reference) 
1.09 (1.08, 1.10) 
 
1.00 (reference) 
0.92 (0.91, 0.93) 
 
1.00 (reference) 
1.06 (1.05, 1.07) 
 
1.00 (reference) 
1.34 (1.33, 1.36) 
Years on 
prescription 
2004 
2005 
2006 
2007 
 
 
1.00 (reference) 
0.90 (0.88, 0.91) 
0.85 (0.84, 0.86) 
0.80 (0.79, 0.82) 
 
 
1.00 (reference) 
1.04 (1.03, 1.05) 
1.06 (1.05, 1.07) 
1.03 (1.02, 1.05) 
 
 
1.00 (reference) 
0.94 (0.93, 0.96) 
0.87 (0.85, 0.88) 
0.82 (0.81, 0.84) 
 
 
1.00 (reference) 
NS 
NS 
NS 
 
 
1.00 (reference) 
1.16 (1.14, 1.17) 
1.33 (1.31, 1.35) 
1.50 (1.48, 1.53) 
 
(CCBs: Calcium Channel Blockers; ACEIs: Angiotensin Converting Enzyme Inhibitors; GOPC: General 
Out-Patient Clinic; FMSC: Family Medicine Specialist Clinic; NS: Not Significant as parameter was excluded 
from initial selection procedure; aOR: adjusted Odds Ratio; The odds ratios for each variable were adjusted for all 
other variables. 
All p values were <0.001 with the following exceptions:*p<0.005; **p<0.05; ***p=0.437)
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Table 3 Factors associated with drug discontinuation and switching within 180 
days 
 
 Drug discontinuation        
                   
Drug switching 
Predictors Bivariate analysis 
Crude Odds ratios 
Adjusted  
Odds Ratiosa
p value 
 
Bivariate analysis 
Crude Odds ratios 
Adjusted  
Odds Ratiosa
p value 
 
Age (years) 
<50  
50-59 
60-69 
> 70 
 
1.88 (1.78, 1.99) 
0.95 (0.90, 1.01) 
0.66 (0.62, 0.71) 
0.83 (0.79, 0.88) 
 
1.00  (reference) 
0.64 (0.60, 0.69) 
0.51 (0.47, 0.56) 
0.65 (0.60, 0.70) 
 
 
<0.001 
<0.001 
<0.001 
 
1.04 (0.95, 1.15) 
1.06 (0.98, 1.16) 
1.09 (1.00, 1.20) 
0.85 (0.78, 0.93) 
 
1.00  (reference) 
0.96 (0.85, 1.07) 
0.97 (0.86, 1.09) 
0.80 (0.71, 0.89) 
 
 
0.421 
0.590 
<0.001 
Sex 
Female 
Male 
 
1.00 (reference) 
1.08 (1.03, 1.14) 
 
 
1.07 (1.02, 1.13) 
 
 
0.012 
 
1.00 (reference) 
0.78 (0.72, 0.84) 
 
 
0.77 (0.71, 0.84) 
 
 
<0.001 
Drug class*  
CCBs 
ACEIs 
Thiazide  
α-blockers 
β-blockers 
 
0.56 (0.52, 0.60) 
1.07 (0.97, 1.19) 
0.76 (0.69, 0.84) 
1.98 (1.79, 2.20) 
2.02 (1.92, 2.13) 
 
1.00 (reference) 
1.38 (1.23, 1.56) 
1.29 (1.15, 1.45) 
3.38 (3.00, 3.82) 
2.38 (2.21, 2.57) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
 
0.84 (0.77, 0.92) 
1.17 (1.00, 1.36) 
2.14 (1.91, 2.40) 
0.71 (0.57, 0.88) 
0.60 (0.54, 0.66) 
 
1.000 (reference) 
1.22 (1.03, 1.45) 
2.16 (1.89, 2.47) 
0.90 (0.72, 1.13) 
0.70 (0.61, 0.79) 
 
 
0.020 
<0.001 
0.358 
<0.001 
(*CCBs: Calcium Channel Blockers; ACEIs: Angiotensin Converting Enzyme Inhibitors. Drug discontinuation is 
defined as the absence of a refill prescription 180 days after the first-ever antihypertensive drug prescribed without 
appearance of another class of antihypertensive agents; Drug switching is defined as the absence of a refill 
prescription 180 days after the first-ever antihypertensive drug prescribed but replaced with another class of 
antihypertensive agent.  The Adjusted Odds ratios were adjusted for age, gender, payment status, service type, 
district of residence, visit type and calendar years on prescription) 
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Table 4 Comparing the prescription patterns of antihypertensive drug classes 
in various countries 
 
 thiazide β-blockers CCB ACEI ARB 
USAa 46% 33% 29% 35% 23% 
UKb 32%* 22% 13%          13% 
Italyc 14%* <3% 43% 50% NA 
Irelandd 15% 23% 9% 18% 3%** 
Japane 20% 20% 50% 15% 11% 
Hong Kongf 13% 46% 49% 19% 0.2% 
(CCB: Calcium channel blockers; ACEI: Angiotensin converting enzyme inhibitors; ARB: angiotensin receptor 
blockers, NA: Not Available.  a: Ma et al, 200634, b: Walley et al, 200337; c: Onder et al, 200138; d: Kabir et al, 
200739; e: Mori et al, 200641; f: the present study.  *including all diuretics; **Losartan and Valsartan only) 
Pending verification 
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 Table on “What is known about topic” 
• Internationally, patterns and trends in antihypertensive prescribing have been well 
described but few studies addressed prescription patterns among Chinese patients 
• Discontinuation and switching profiles have also been extensively studied in 
Caucasian populations but few among ethnic Chinese 
What this study adds 
• From a total of 1,069,836 antihypertensive drug visits (67,028 patients), the most 
commonly prescribed drugs were calcium channel blockers (CCBs) [49%], 
beta-blockers (46%) and Angiotensin-Converting Enzyme Inhibitors (19%), with 
thiazide diuretic being low (13%) and its annual prescription trend on the decline.  
• Drug discontinuation was highest for BBs (21%) and lowest for CCBs (12%), 
while switching was less common than discontinuation and was most likely with 
thiazide diuretics.   
• CCBs may be a particularly favorable antihypertensive treatment in Chinese and 
the high discontinuation rates of beta-blockers supported international guidelines 
advising against its use as a first-line therapy generalizable also to Chinese 
patients. 
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 Figure 1 Annual trend of antihypertensive drug prescription in primary care 
clinics in Hong Kong 
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